Follow-up of patients with advanced melanoma

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to follow a national cohort of patients diagnosed with resectable stage II, III, or IV melanoma, as well as those with unresectable primary melanoma. It focuses on collecting clinico-epidemiological and biological data to identify new prognostic and predictive factors related to melanoma. The study will also assess the economic impact of innovative treatments and their associated toxicities. By analyzing various factors, including genomic alterations and individual immunological profiles, the study seeks to improve the prognosis for advanced melanoma patients.

Why it matters

Who can join: the full rules

1. Cohort Patients with Resectable stage II or III

   Inclusion Criteria:

   Patients diagnosed with resectable stage IIA/IIB/IIC or III melanoma, confirmed by histological exam.

   Naïve of systemic treatment for resectable stage II or III. Whose metastatic tumoral material can be collected by the Biological Resource Centers (optional criteria).

   Aged ≥ 18 years. Consenting to participate (signed informed consent).

   Exclusion Criteria:

   Patients refusal. Choroid melanoma. Resectable stage 1 melanoma. Stage 4, unresectable primitive or unresectable stage 3 melanoma. Patients under guardianship and under trusteeship.
2. Cohort patients with Unresectable stage III or stage IV (resectable or not) or unresectable primary:

Inclusion Criteria:

Patients diagnosed with an advanced melanoma, confirmed by histological exam. Unresectable primitive or unresectable stage III or stage IV (resectable or not) melanoma ; or patients treated by neoadjuvant treatment (exceptional) Naïve of systemic treatment for unresectable primitive or unresectable stage III or stage IV (resectable or not) melanoma, except adjuvant treatment.

Whose metastatic tumoral material can be collected by the Biological Resource Centers (optional criteria).

Aged ≥ 18 years. Consenting to participate (signed informed consent).

Exclusion Criteria:

Resectable stage 1, 2 or 3 melanoma. Patients refusal. Choroid melanoma. Patients under guardianship and under trusteeship.

Where it's running

• CHU d'Amiens
  Amiens, France Recruiting
• CH Annecy Genevois
  Annecy, France Recruiting
• CHU de Besançon
  Besançon, France Recruiting
• Assistance Publique - Hôpitaux de Paris (AP-HP), Hôpital Avicennes
  Bobigny, France Recruiting
• CHU de Bordeaux Hôpital Saint-André
  Bordeaux, France Recruiting
• CHU de Brest
  Brest, France Recruiting

Study contacts

• Study coordinator: Celeste Lebbe, MD, PhD
• Email: celeste.lebbe@aphp.fr
• Phone: +33142494679

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Social prescriptions and micro-learning to improve cancer care

  This study tests a multicomponent program using social prescriptions and short online learning to help cancer patients and their chosen support persons in Germany.

  Recruiting University of Regensburg · Augsburg, Bavaria and 7 other locations · NCT07788729

• TCC1727 combined with other cancer medicines for adults with advanced solid tumors

  This phase Ib/II trial tests TCC1727 given with benmelstobart, olaparib, or topotecan in adults with advanced solid tumors to find safe doses and see if the combinations help control tumors.

  Recruiting Phase 1/2 Beijing Tide Pharmaceutical Co., Ltd · Beijing, Beijing Municipality and 2 other locations · NCT07371663

• Regular supervised exercise to reduce symptoms in melanoma

  This trial tests whether a 12-week supervised exercise program can reduce fatigue and improve quality of life for adults with stage IIb–IV melanoma who are receiving immunotherapy or targeted therapy.

  Recruiting Universität Duisburg-Essen · Essen · NCT06985056

• Video consultations for cancer treatment recommendations

  This study is testing if video consultations can help patients with malignant melanoma get better treatment recommendations by connecting them with cancer experts from different specialties, no matter where they live.

  Recruiting University Hospital Muenster · Bonn and 2 other locations · NCT06980740

• Testing a new antibody treatment for advanced solid tumors and liver cancer

  This study is testing a new antibody treatment for people with advanced solid tumors and liver cancer to see if it is safe and how well it works.

  Recruiting at 5 sites Phase 1 Chiome Bioscience Inc. · Kashiwa, Chiba and 4 other locations · NCT06636435

• Using PSMA-PET to guide melanoma surgery planning

  We will see if a PSMA PET/CT scan can find melanoma spread more clearly than the standard FDG PET/CT in adults with palpable lymph nodes or limited metastatic melanoma who are scheduled for surgery.

  Recruiting Phase 2 Royal Marsden NHS Foundation Trust · London · NCT06560905

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.